Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes

xlomafota13 shared this article with you from Inoreader Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes Via Head & Neck Abstract Background There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC). Methods Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1–5 lesions) at any point during follow-up. Results There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14–0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02–0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07–0.71). Conclusions There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.